Anticancer potential of albumin bound wnt/beta-catenin pathway inhibitor niclosamide in breast cancer cells

Basit Öğe Kaydı
dc.authoridEngin Ulukaya / 0000-0003-4875-5472en_US
dc.authoridMerve Erkısa Genel / 0000-0002-3127-742X
dc.authorscopusidEngin Ulukaya / 6602927353
dc.authorscopusidMerve Erkısa Genel / 57126208900
dc.authorwosidMerve Erkısa Genel / AAM-1001-2020en_US
dc.authorwosidEngin Ulukaya / K-5792-2018
dc.contributor.authorArı, Ferda
dc.contributor.authorErkısa Genel, Merve
dc.contributor.authorPekel, Gonca
dc.contributor.authorErtürk, Elif
dc.contributor.authorBüyükköroğlu, Gülay
dc.contributor.authorUlukaya, Engin
dc.date.accessioned2022-04-06T05:40:54Z
dc.date.available2022-04-06T05:40:54Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesien_US
dc.description.abstractAlbumin-based nanoparticle transport systems (nab-technology) are a new strategy in cancer treatment and we aimed to increase the effectiveness of Niclosamide using this technology. Niclosamide was bound with bovine serum albumin (BSA) by desolvation to yield nanoparticle albumin-bound Niclosamide (nab-Niclo). Nab-Niclo anticancer activity was assessed by proliferation, apoptosis and DNA damage analyses on breast cancer cells. The results implied that nab-Niclo was a more potent agent in the inhibition of cell viability than free Niclosamide and albumin. Flow cytometry analysis show that nab-Niclo triggered apoptosis by caspase and mitochondriadependent pathways in cells and nab-Niclo enhances apoptosis by induce DNA damage in cells. Overall results of this study showed that the nanoparticle form of Niclosamide is effective for breast cancer treatment, presenting a new treatment strategy that can be safe and effective for breast cancer patients.en_US
dc.identifier.citationAri, F., Erkisa, M., Pekel, G., Erturk, E., Buyukkoroglu, G., Ulukaya, E. (2021). Anticancer Potential of Albumin Bound Wnt/beta-Catenin Pathway Inhibitor Niclosamide in Breast Cancer Cells. Chemistryselect, 6(29), 7463-7475.en_US
dc.identifier.doi10.1002/slct.202100819en_US
dc.identifier.endpage7475en_US
dc.identifier.issn2365-6549en_US
dc.identifier.issue29en_US
dc.identifier.startpage7463en_US
dc.identifier.urihttps://doi.org/10.1002/slct.202100819
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2609
dc.identifier.volume6en_US
dc.identifier.wosWOS:000765993600005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorErkısa Genel, Merve
dc.institutionauthorUlukaya, Engin
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofCHEMISTRYSELECTen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlbuminen_US
dc.subjectApoptosisen_US
dc.subjectBreast Canceren_US
dc.subjectNanoparticlesen_US
dc.subjectNiclosamideen_US
dc.titleAnticancer potential of albumin bound wnt/beta-catenin pathway inhibitor niclosamide in breast cancer cellsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
ChemistrySelect - 2021 - Ari - Anticancer Potential of Albumin Bound Wnt ‐Catenin Pathway Inhibitor Niclosamide in Breast.pdf
Boyut:
2.5 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Makale Koleksiyonu